2017 Dream Team Projects
Jaclyn Schwartz
Tiffany Ho
Erika Manczak
The goal of this longitudinal study is to leverage a well-characterized sample of healthy adolescents who experienced early life stress to integrate multi-system neurobiological and digital phenotypes with machine learning algorithms to identify risk factors and mechanistic targets involved in the onset of depression and engagement in suicidal behaviors. This project will facilitate the development of more timely and precise approaches to the prevention of these debilitating conditions and their devastating consequences.
Our approach is three-pronged:
- Integrate existing and new assessments of neurobiologically (functional and structural MRI, cortisol, immune function) and digitally (sleep, mobility, affective states) derived phenotypes measured prior to the onset of disorder to identify adolescents who are at risk for developing clinically significant depression and engaging in suicidal behaviors
- Use machine learning algorithms suited for multidimensional prediction to create a risk calculator that can be scaled and incorporated into existing health assessments
- Refine the algorithms by applying the risk calculator to data from larger national and international samples of children and young adolescents, allowing us to quantify risk before the first onset of depression and engagement in suicidal ideation
Because we are studying adolescents, we are uniquely positioned to characterize the early emergence of depression and suicidal behaviors that, if undetected, often cascade into lifelong difficulties. Our goal is perfectly aligned with the mission of PHIND to fundamentally revolutionize health care, and specifically, precision mental health.
Frederick Chin
Erika Manczak
The Predicting Health in Aging (PHIA) project will address two major precision health goals, leveraging a deeply characterized cohort of 200 healthy older individuals from whom baseline measures of brain structure, brain function, genetics, and CSF biomarkers of risk for Alzheimer’s disease (AD) are collected. PHIA’s first goal is to include a longitudinal follow up assessment that will seek to identify critical biomarkers that predict changes in cognitive and neurobiological health that occur 3.5 years after baseline assessment. PHIA’s second goal is to incorporate additional novel MRI metrics and Tau PET imaging to establish how brain regions known to be impacted early in AD (a) contribute to early changes in memory performance and (b) ultimately predict risk of AD dementia onset over a 7-year window. By using cutting-edge imaging modalities, blood-based and genetic assays, and multivariate analytics to predict the transition from normal to pathological aging, this project will improve the ability to predict long-term health vs. risk of dementia among clinically asymptomatic individuals.
Aim
Develop a novel cfDNA sequencing technology and deep learning analytical framework that achieves state-of-the-art accuracy in distinguishing normal versus pathologic states and tissue-of-origin from clinical samples.
Overarching Objective
A scalable and robust non-invasive assay to detect cancer early, when it is most curable.